Aarti Drugs Limited (NSE:AARTIDRUGS)
470.35
+8.20 (1.77%)
Jun 9, 2025, 1:30 PM IST
Aarti Drugs Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 75.6 | 94.32 | 89.6 | 223.3 | 97.79 | Upgrade
|
Short-Term Investments | 150.5 | 108.89 | 113.3 | 120.51 | 122.05 | Upgrade
|
Cash & Short-Term Investments | 226.1 | 203.2 | 202.89 | 343.81 | 219.84 | Upgrade
|
Cash Growth | 11.27% | 0.15% | -40.99% | 56.39% | 15.31% | Upgrade
|
Accounts Receivable | 7,512 | 7,046 | 8,648 | 7,499 | 5,552 | Upgrade
|
Other Receivables | 100 | 47.17 | 39.11 | 6.98 | 24.37 | Upgrade
|
Receivables | 7,619 | 7,095 | 8,691 | 7,506 | 5,577 | Upgrade
|
Inventory | 4,729 | 4,859 | 5,163 | 5,259 | 4,150 | Upgrade
|
Other Current Assets | 808.7 | 1,050 | 861.42 | 824.5 | 621.43 | Upgrade
|
Total Current Assets | 13,384 | 13,207 | 14,918 | 13,934 | 10,568 | Upgrade
|
Property, Plant & Equipment | 11,891 | 10,351 | 8,622 | 7,665 | 6,844 | Upgrade
|
Long-Term Investments | 224.1 | 199.74 | 187.99 | 194.8 | 173.01 | Upgrade
|
Other Intangible Assets | 71.5 | 368.24 | 243.34 | 1.53 | 2.55 | Upgrade
|
Other Long-Term Assets | 176.4 | 197.04 | 242.33 | 284.36 | 72.61 | Upgrade
|
Total Assets | 25,747 | 24,324 | 24,214 | 22,080 | 17,660 | Upgrade
|
Accounts Payable | 4,161 | 4,496 | 4,925 | 4,687 | 3,300 | Upgrade
|
Accrued Expenses | 42.9 | 71.78 | 91.65 | 76.77 | 171.92 | Upgrade
|
Short-Term Debt | - | 2,147 | 3,605 | 3,563 | 1,572 | Upgrade
|
Current Portion of Long-Term Debt | 3,282 | 723.83 | 412.96 | 435 | 396.08 | Upgrade
|
Current Portion of Leases | 11.8 | 9.5 | 19.92 | 25.97 | 27.97 | Upgrade
|
Current Income Taxes Payable | - | 11.81 | 42.33 | - | - | Upgrade
|
Other Current Liabilities | 871.2 | 495.39 | 397.13 | 612.7 | 485.77 | Upgrade
|
Total Current Liabilities | 8,370 | 7,955 | 9,495 | 9,401 | 5,954 | Upgrade
|
Long-Term Debt | 2,840 | 2,753 | 2,047 | 1,385 | 1,476 | Upgrade
|
Long-Term Leases | 16.5 | 9.14 | 4.03 | 18.79 | 35.8 | Upgrade
|
Long-Term Unearned Revenue | 1.6 | 1.7 | 1.7 | 1.7 | 1.7 | Upgrade
|
Long-Term Deferred Tax Liabilities | 782.3 | 757.07 | 709.68 | 724.31 | 771.34 | Upgrade
|
Other Long-Term Liabilities | -0.04 | -0 | - | 157.45 | 269.89 | Upgrade
|
Total Liabilities | 12,053 | 11,504 | 12,287 | 11,717 | 8,526 | Upgrade
|
Common Stock | 912.7 | 919.35 | 926 | 926 | 932 | Upgrade
|
Retained Earnings | - | 11,701 | 10,811 | 9,240 | 8,018 | Upgrade
|
Comprehensive Income & Other | 12,777 | 194.75 | 187.48 | 197.4 | 184.54 | Upgrade
|
Total Common Equity | 13,690 | 12,815 | 11,924 | 10,364 | 9,134 | Upgrade
|
Minority Interest | 3.44 | 4.06 | 2.33 | -0.6 | -0.17 | Upgrade
|
Shareholders' Equity | 13,693 | 12,820 | 11,927 | 10,363 | 9,134 | Upgrade
|
Total Liabilities & Equity | 25,747 | 24,324 | 24,214 | 22,080 | 17,660 | Upgrade
|
Total Debt | 6,151 | 5,643 | 6,089 | 5,428 | 3,508 | Upgrade
|
Net Cash (Debt) | -5,925 | -5,440 | -5,886 | -5,084 | -3,288 | Upgrade
|
Net Cash Per Share | -64.65 | -59.17 | -63.57 | -54.91 | -35.28 | Upgrade
|
Filing Date Shares Outstanding | 91.37 | 91.94 | 92.6 | 92.6 | 93.2 | Upgrade
|
Total Common Shares Outstanding | 91.37 | 91.94 | 92.6 | 92.6 | 93.2 | Upgrade
|
Working Capital | 5,014 | 5,252 | 5,423 | 4,533 | 4,614 | Upgrade
|
Book Value Per Share | 149.84 | 139.40 | 128.77 | 111.92 | 98.01 | Upgrade
|
Tangible Book Value | 13,619 | 12,447 | 11,681 | 10,362 | 9,132 | Upgrade
|
Tangible Book Value Per Share | 149.05 | 135.39 | 126.14 | 111.90 | 97.98 | Upgrade
|
Land | - | 937.67 | 937.67 | 934.6 | 649.81 | Upgrade
|
Buildings | - | 2,257 | 1,932 | 1,921 | 1,882 | Upgrade
|
Machinery | - | 10,633 | 9,122 | 8,792 | 8,383 | Upgrade
|
Construction In Progress | - | 2,252 | 1,868 | 767.37 | 192.57 | Upgrade
|
Updated Jan 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.